611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Some California Mosquitoes Can Carry Zika VirusHealth Tip: Managing Rheumatoid ArthritisHealth Tip: Avoiding Lyme Disease2.5 Million U.S. High School Students Had a Concussion in Past YearMany With Severe Allergies Don't Carry an EpiPen: StudyHealth Tip: Understanding MonoParkinson's Meds Tied to Higher Rate of Gambling, Sex Addiction Than ThoughtIf Opioid Addicts Survive OD, Other Hazards Lie Ahead: StudyHealth Tip: Create a Food Allergy PlanHealth Tip: Learn Warning Signs of Heat StrokeFlorida Teen First Human Case of Another Mosquito-Borne VirusExercise May Ease Inflammation Tied to ObesityAfter Concussion, Are Legs at Risk, Too?AHA: New Insights Into Sickle Cell and Stroke RiskSevere Stress May Send Immune System Into OverdriveMarriage Is Good Medicine for the HeartObesity Plagues Rural AmericaReduce Weight, Reduce the Arthritic Knee PainHealth Tip: Travel-Related Ills May Surface After You ReturnHealth Tip: What to Do if You Scratch Your EyeDoes Salt Water Help Your Cut? And Other Health Myths of SummerObesity's a Larger Problem in Rural AmericaDiabetes Linked to Risk for Parkinson's Disease60 Sickened So Far in Salmonella-Tainted Melon OutbreakSurgical Blood Transfusions Tied to Clot RiskWhy Are Statins Underused With Black Patients?U.S. Obesity Rates Rising AgainHealth Tip: Caring for a Minor BurnCould You Have Rosacea?Kitchen Towels Laden With BacteriaWalkable Neighborhoods Might Lower Kids' Asthma RiskWind Turbines' Health Impact Still Up in the AirAllergies More Common in Kids With AutismHealth Tip: Breathe Easier in a Volcano ZoneThink Twice About Tonsil, Adenoid RemovalColonoscopies, Endoscopies Carry Greater Infection Risk Than Thought: StudyYour Tummy Rumblings Might Help Diagnose Bowel DisorderHealth Tip: Three Weight Stats That Can Predict HealthHealth Tip: What To Expect From Joint Replacement SurgeryNon-Drug Migraine Treatments Often IgnoredTips for Handling a Medical EmergencyYes, You Can Put Too Much Chlorine in a PoolA Nasty Germ That Can Lurk in Favorite FoodsFirst Artificial Iris is ApprovedNew Treatment for Ulcerative Colitis ApprovedThe ER or Urgent Care?Widely Used Antibacterial Tied to Colon Woes in MiceAnother Drug to Prevent Migraines Shows PromiseNew Treatment Approved for Rare Disease PKULittle Follow-Up for Many Concussion Patients
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures


HealthDay News
Updated: May 21st 2018

new article illustration

MONDAY, May 21, 2018 (HealthDay News) -- Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure.

Doptelet was evaluated in a pair of clinical studies involving a total of 435 people with chronic liver disease and severe thrombocytopenia. The results showed that, compared to those treated with placebo, a higher proportion of patients treated with Doptelet had increased platelet counts and did not require platelet transfusion or any rescue therapy on the day of the procedure and up to seven days following the procedure.

The most common side effects included fever, abdominal pain, nausea, headache, fatigue, and swelling of the hands or feet. An elevated risk of blood-clot formation was a less common but more serious adverse reaction, the FDA said.

"Patients with chronic liver disease who have low platelet counts and require a procedure are at increased risk of bleeding," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "Doptelet was demonstrated to safely increase the platelet count. This drug may decrease or eliminate the need for platelet transfusions, which are associated with risk of infection and other adverse reactions."

The drug is produced by the Japanese pharma firm AkaRx.

More Information